Brief: Cartesian Therapeutics Says Topline Data From Phase 2B Study Of Descartes-08 In Myasthenia Gravis (Mg) Is Expected In Mid-2024
05/03/2024 12:05
March 5 (Reuters) - Cartesian Therapeutics Inc RNAC.O :
* CARTESIAN THERAPEUTICS INC - TOPLINE DATA FROM PHASE 2B
STUDY OF
DESCARTES-08 IN MYASTHENIA GRAVIS (MG) IS EXPECTED IN MID-2024
Source text for Eikon: ID:nGNX3Ngw18
Further company coverage: RNAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview